awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47861831-0FE11C3C-A361-479B-A8C2-81C004E8374E
Q47861831-0FE11C3C-A361-479B-A8C2-81C004E8374E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47861831-0FE11C3C-A361-479B-A8C2-81C004E8374E
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
P2860
Q47861831-0FE11C3C-A361-479B-A8C2-81C004E8374E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47861831-0FE11C3C-A361-479B-A8C2-81C004E8374E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f69b3eb2f138442ebfd81023d47c42d010894ecb
P2860
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.